Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 96Stomach Neoplasms 53Rectal Neoplasms 49Pancreatic Neoplasms 42Colonic Neoplasms 34Esophageal Neoplasms 30Neoplasm Metastasis 28Neoplasms 23Adenocarcinoma Of Esophagus 19Adenocarcinoma 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Lymphoma, Large B-Cell, Diffuse 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Esophageal Squamous Cell Carcinoma 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Liver Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Recurrence 4Lymphoma, Non-Hodgkin 4Gastrointestinal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Bile Duct Neoplasms 4Peritoneal Neoplasms 3Pancreatic Adenocarcinoma 3Leukemia 3Fallopian Tube Neoplasms 3

Interventions

Everolimus 4Temozolomide 3Octreotide 2Capecitabine 2Bevacizumab 2temsirolimus 1regorafenib 1pazopanib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1Sunitinib 1Sorafenib 1Sirolimus 1Oxaliplatin 1Leucovorin 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Fentanyl 1Doxorubicin 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Islet Cell × Oxaliplatin × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡